Pulmotech MAA Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of pulmonary embolism cases, expansion of nuclear medicine departments in hospitals, availability of technetium-based radiopharmaceuticals, growth in diagnostic imaging procedures, rising clinical acceptance of lung scintigraphy.

The growth in the forecast period can be attributed to increasing demand for early and accurate pulmonary diagnostics, rising investments in nuclear medicine infrastructure, expansion of clinical research using radiotracers, growing focus on personalized diagnostic imaging, technological advancements in imaging agents. Major trends in the forecast period include increasing adoption of advanced lung perfusion imaging agents, rising use of nuclear medicine in pulmonary diagnostics, growing demand for accurate pulmonary embolism detection, expansion of radiopharmaceutical clinical applications, enhanced focus on imaging accuracy and safety.

The rising prevalence of respiratory diseases is anticipated to drive the growth of the pulmotech MAA market in the coming years. Respiratory diseases encompass a wide range of conditions that impact the lungs and other components of the respiratory system, including the airways, lungs, and respiratory muscles. The increasing prevalence of these diseases is influenced by factors such as environmental pollution, lifestyle habits, an aging population, and advancements in diagnostic technologies. Pulmotech MAA is used in the diagnosis and management of chronic respiratory conditions by supporting pulmonary imaging to evaluate regional lung function and identify potential abnormalities such as perfusion deficits. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based health and welfare agency, around 8.5 million people in Australia, representing 34% of the population, were estimated to be living with chronic respiratory conditions. This figure includes approximately 2.8 million individuals, or 11% of the population, affected by asthma and 638,000 individuals, or 2.5% of the population, living with chronic obstructive pulmonary disease (COPD). Therefore, the increasing prevalence of respiratory diseases is contributing to the growth of the pulmotech MAA market.

The growing aging population is expected to support the expansion of the pulmotech MAA market in the future. An aging population refers to a demographic trend in which the proportion of older individuals, typically those aged 65 years and above, increases. This expansion is largely driven by longer life expectancy resulting from advancements in healthcare, improved living standards, and better control of chronic illnesses. Pulmotech MAA benefits the aging population by facilitating detailed pulmonary imaging to diagnose and monitor age-related respiratory conditions, enabling timely and accurate treatment decisions. For example, in January 2024, statistics released by the Population Reference Bureau (PRB), a US-based nonprofit organization, projected that the number of Americans aged 65 and older would rise from 58 million in 2022 to 82 million by 2050, reflecting a 47% increase, with their share of the total population growing from 17% to 23%. As a result, the expanding aging population is fueling the growth of the pulmotech MAA market.

The increasing prevalence of chronic diseases is expected to drive the growth of the pulmotech MAA market in the coming years. Chronic diseases are medical conditions that persist over long periods, often lasting for many years or throughout an individual’s lifetime. The rise in chronic diseases is mainly attributed to lifestyle changes, aging populations, and environmental influences. Pulmotech MAA plays an important role in addressing the growing burden of chronic diseases, particularly those that affect the respiratory system. It is used in the evaluation and management of chronic conditions by providing accurate imaging of pulmonary perfusion, assisting in the diagnosis of disorders such as pulmonary embolism, and supporting the monitoring of lung-related diseases. For instance, in April 2025, data from the National Center for Health Statistics (NCHS) under the Centers for Disease Control and Prevention (CDC), a US-based health statistics publication, highlighted an upward trend in chronic diseases, especially among young and middle-aged adults. Among young adults, obesity prevalence rose from 27.3% in 2023, while depression increased from 25%, alongside higher rates of diabetes and chronic kidney disease among midlife adults. Therefore, the growing prevalence of chronic diseases is expected to support the expansion of the pulmotech MAA market.

Major companies operating in the pulmotech maa market are Curium Pharma.

North America was the largest region in the pulmotech MAA market in 2025. The regions covered in the pulmotech maa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pulmotech maa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the pulmotech maa market by increasing costs of imported radioisotopes, specialized laboratory reagents, sterile packaging materials, and nuclear medicine handling equipment required for radiopharmaceutical production and distribution. Hospitals and diagnostic imaging centers in North America and Europe are most affected due to reliance on imported technetium supply chains, while Asia-Pacific faces procurement challenges for advanced imaging agents. These tariffs are increasing operational costs and affecting pricing of diagnostic procedures. However, they are also encouraging regional radioisotope production, localized radiopharmaceutical manufacturing, and strengthened domestic supply chain capabilities.

The pulmotech maa market research report is one of a series of new reports that provides pulmotech maa market statistics, including pulmotech maa industry global market size, regional shares, competitors with a pulmotech maa market share, detailed pulmotech maa market segments, market trends and opportunities, and any further data you may need to thrive in the pulmotech maa industry. This pulmotech maa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pulmotech MAA is a radiopharmaceutical product utilized in lung scintigraphy to assess pulmonary blood flow. It is composed of technetium Tc 99m-tagged aggregated human serum albumin particles that, after intravenous administration, temporarily lodge within the pulmonary capillary network, enabling visualization of lung perfusion.

The primary uses of Pulmotech MAA include the diagnosis of pulmonary embolism, preoperative evaluation, assessment of lung transplant suitability, analysis of chronic respiratory conditions, and clinical research applications. Pulmonary embolism (PE) refers to an obstruction in one of the pulmonary arteries, most often resulting from blood clots. The product is distributed through direct sales, distributors, and online platforms, and it is used by a range of end users, including hospitals, research organizations, and diagnostic imaging centers.

The pulmotech MAA market consists of sales of radiopharmaceutical Kits, ready-to-use radiopharmaceuticals, imaging system integration, and emerging product variants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.